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Background: Cognitive impairment after sepsis is an important clinical problem. Determinants
of postseptic cognitive impairment are not well understood. We thus undertook a systems biology
approach to exploring a possible role for apolipoprotein E (APOE) in postseptic cognitive
impairment.
Design: Prospective, observational cohort.
Setting: Intermountain Medical Center, a tertiary referral center in Utah.
Patients/Participants: Patients with sepsis admitted to study intensive care units.
Interventions: None.
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Methods: We obtained peripheral blood for deep sequencing of RNA and followed up survivors
at 6 months with a battery of cognitive instruments. We defined cognitive impairment based on
the 6-month Hayling test of executive function. In our primary analysis, we employed weighted
network analysis. Secondarily, we compared variation in gene expression between patients with
normal versus impaired cognition.
Measurements and Main Results: We enrolled 40 patients, of whom 34 were follow-up
eligible and 31 (91%) completed follow-up; 1 patient’s RNA sample was degraded—the final
analytic cohort was 30 patients. Mean Hayling test score was 5.8 (standard deviation 1.1), which
represented 20% with impaired executive function. The network module containing APOE was
dominated by low-expression genes, with no association on primary analysis (P = .8). Secondary
analyses suggested several potential lines of future investigation, including oxidative stress.
Conclusions: In this prospective pilot cohort, executive dysfunction affected 1 in 5 survivors of
sepsis. The APOE gene was sparsely transcribed in peripheral leukocytes and not associated with
cognitive impairment. Future lines of research are suggested.

Author Manuscript

Keywords
sepsis; cognitive impairment; peripheral blood transcriptome

Introduction
Sepsis, a life-threatening infection associated with organ dysfunction, is a significant public
health problem, with an annual incidence of 750 000 in the United States and an associated
mortality of 20% to 50%.1 Clinical advances and research successes over the last 20 years
have significantly reduced sepsis mortality.2 The increasing number of sepsis survivors has
allowed researchers to identify substantial, persistent health impairments among survivors of
critical illness, including sepsis, now commonly termed postintensive care syndrome.3

Author Manuscript

Sepsis is associated with an acute syndrome of delirium often termed sepsis-associated
encephalopathy among the majority of patients.4,5 Sepsis-associated encephalopathy is
an important predictor of later cognitive impairment.6,7 Once thought to be a temporary
problem, there is now mounting evidence that cognitive impairment is a serious and
common problem after septic shock. Between 25% and 75% of survivors will be affected
by cognitive impairment after hospital discharge.8,9 Cognitive impairment regardless of
etiology is associated with substantial functional, medical, and financial impairments.10–12

J Intensive Care Med. Author manuscript; available in PMC 2022 January 03.

Brown et al.

Page 3

Author Manuscript

The causes of postseptic cognitive impairment are not well understood,13 although some
markers of illness severity at hospital discharge do predict cognitive impairment,14 and
a small cohort within a randomized controlled trial suggested that aggressive diuresis
(“conservative fluids”) may be associated with worse cognitive impairment.15 Cellular
hypoxia, which can occur as a result of hypoxemia, inadequate cardiac output, or
microvascular dysfunction, may all contribute.16 Cognitive impairment may also be related
to sedative administration, although data have been equivocal to date.17,18 An important
candidate pathway with promising early results in cognitive impairment caused by other
insults is the apolipoprotein pathway,19,20 although other pathways may also be important.
Evidence suggests that while most relevant lipid peroxidation occurs in neuronal tissue,
leukocytes (especially monocytes/macrophages21,22) express apolipoprotein E (APOE) in
multiple disease states.23–26 We therefore undertook a prospective exploratory study of the
peripheral blood transcriptome in patients with sepsis. Some aspects of the study design
have been reported elsewhere.27

Author Manuscript

Materials and Methods
Study Design
This prospective, observational study enrolled patients with sepsis admitted to the
intensive care units (ICUs) of Intermountain Medical Center, a 450-bed academic referral
hospital in Murray, Utah. The study was retrospectively registered with clinicaltrials.gov
(NCT03015584), with the primary analysis plan prespecified before any data were reviewed.
Patient Population
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We studied adult (≥18 years) patients with sepsis according to SEPSIS-3 definitions
(suspected infection and organ dysfunction as manifested by an increase in SOFA score
≥2 over baseline)1 admitted to a study ICU. Patients were enrolled within 48 hours of
ICU admission. We excluded patients with preexisting do not resuscitate/do not intubate
orders, primary diagnosis of stroke or intracranial hemorrhage, known preexisting dementia
or substantial cognitive impairment of any cause (established from both chart review and/or
a score >3 on Informant Questionnaire on Cognitive Decline in the Elderly28 screening
if concern raised from chart review), prior cardiac surgery, known schizophrenia or other
psychotic thought disorder, known pregnancy, primary diagnosis of drug overdose, attending
physician deemed aggressive care unsuitable, or residence >250 miles from Intermountain
Medical Center. Participants who died before 6 months were excluded from analysis.
Patient Data
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We collected blood for whole blood RNA deep sequencing at study enrollment and ICU
discharge. We also collected demographic, comorbidity, and acute severity of illness data.
Outcomes were assessed at hospital discharge, 3, and 6 months, with the primary outcome
assessed at 6 months. Outcome measures were administered in person by a trained research
coordinator, using standardized instruments. The cognitive battery included verbal fluency
(letters F, A, S), digit span (forward and backward) and similarities subtests of the Wechsler
Adult Intelligence Scale-IV, Logical Memory I and II from the Wechsler Memory Scale-IV,
and the Hayling Sentence Completion Test from the Hayling and Brixton tests.
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The Hayling Sentence Completion test (hereafter “Hayling test”) was our primary outcome.
The Hayling test is a well-validated measure of executive function29 and has been used as
a key outcome measure in some studies of critical illness survivors.15,30 Executive function
is a central cognitive domain, crucial to overall human function and quality of life,31,32 and
is one of the most commonly impaired cognitive domains in survivors of critical illness and
sepsis.33
Primary Analysis
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For this study, the prespecified primary analysis of the association between the eigengene
of the APOE network module from weighted network analysis (WNA; see below) and
the 6-month Hayling test was performed. Where a patient had a 3-month follow-up but
missed 6-month follow-up, we performed single imputation based on regression of 3-month
on 6-month outcomes among other patients. In a sensitivity analysis, we used a linear
regression of module eigengene versus Hayling test, controlling for age and sex.
Secondary Analyses

Author Manuscript

In a post hoc exploratory analysis, we used standard bioinformatics approaches and a false
discovery rate limited to 5% to determine which genes were differently expressed between
patients with abnormal versus normal Hayling test at 6 months. We used the established
threshold of 5.5 to define abnormality in the Hayling test. This analysis was performed
to identify potential candidate pathways for future study. In another post hoc exploratory
analysis (see Supplementary Material for details), we performed a new WNA after removal
of low-expression genes. In another post hoc secondary analysis, we used traditional
bioinformatics methods to evaluate differentially expressed genes between patients who
were ever delirious (defined as any Confusion Assessment Method [CAM]-ICU score
positive during the ICU stay) or never delirious (no positive CAM-ICU score during the
ICU stay).
Laboratory Methods
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Blood was drawn in PAXgene tubes and immediately frozen at −20°C. We extracted RNA
from peripheral whole blood using PAXgene Blood RNA Kit IVD (Qiagen Cat #762164,
Germantown, MD) with approximately 1 μg of RNA isolated from whole blood; 100 ng
of this RNA was used for Next Generation RNA sequencing (using the Illumina kits with
Ribo-Zero Globin processing, 50 cycle single read), aligned to H_sapiens_Feb_2009_B37.
Total RNA samples (100-500 ng) were hybridized with Ribo-Zero Globin to substantially
deplete both globin RNA and ribosomal RNA species from the samples. Stranded RNA
sequencing libraries were prepared as described using the Illumina (San Diego, CA) TruSeq
Stranded Total RNA Kit with Ribo-Zero Globin (RS-122-2501 and RS-122-2502). Purified
libraries were qualified on an Agilent Technologies (Santa Clara, CA) 2200 TapeStation
using a D1000 ScreenTape assay (cat# 5067-5582 and 5067-5583). The molarity of adaptermodified molecules was defined by quantitative polymerase chain reaction using the Kapa
Biosystems (Wilmington, MA) Kapa Library Quant Kit (cat#KK4824). Individual libraries
were normalized to 10 nmol/L and equal volumes were pooled in preparation for Illumina
sequence analysis. Sequencing libraries (25 pmol/L) were chemically denatured and applied
to an Illumina HiSeq v4 single read flow cell using an Illumina cBot. Hybridized molecules
J Intensive Care Med. Author manuscript; available in PMC 2022 January 03.
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were clonally amplified and annealed to sequencing primers with reagents from an Illumina
HiSeq SR Cluster Kit v4-cBot (GD-401-4001). Following transfer of the flowcell to an
Illumina HiSeq 2500 instrument (HCSv2.2.38 and RTA v1.18.61), a 50-cycle single-read
sequence run was performed using HiSeq SBS Kit v4 sequencing reagents (FC-401-4002).
Bioinformatics Analysis
Reads were aligned to the human GRCh38 genome from Ensembl release 87 using STAR
version 2.5.2b34 with splice junctions optimized for 50 base pair reads. Reads were trimmed
of adapters and aligned to the reference database using STAR in 2 pass mode to output
a BAM file sorted by coordinates. Mapped reads were assigned to annotated genes using
feature-Counts version 1.5.1.35 Normalized counts and differentially expressed genes were
identified using DESeq2.36

Author Manuscript

We used DAVID for the pathway analysis and defined significant pathways on the basis of
an adjusted P value < .05 and a z-score whose absolute value was greater than 2.
For the primary prespecified analysis, we used WNA37 to analyze the transcriptome (details
in Supplementary Material). We compared module eigengenes using the Wilcoxon rank-sum
statistic. When WNA was uninformative (due to large numbers of low-level transcripts,
including APOE) for the primary analysis, we compared expression within transcriptomes
between patients with and without cognitive impairment as assessed by the 6-month Hayling
test. We used DAVID and R Bioconductor and defined significant pathways on the basis of
an adjusted P value < .05 and a z-score whose absolute value was greater than 2.
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To address the risk of type 1 error arising from multiple comparisons, where applicable, we
limited the false discovery rate to <5% using the technique of Benjamini and Hochberg.38
We performed analyses in R version 3.2.3 (www.r-project.org).39
Sample Size
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Although this study was primarily intended to generate hypotheses and provide relevant
effect estimates for subsequent studies, we estimated that 40 enrolled patients with a
12% mortality (based on local experience40) and a 6% loss to follow-up (based on
prior experience41) would provide 33 patients for follow-up. Assuming a 40% incidence
of cognitive impairment (ie, 13 patients with impairment, 20 without impairment), for
RNA-seq, we had 80% power to detect a 1.5-fold change in gene expression with a 0.05
proportion of differentially expressed genes at a 0.05 false discovery level with average
standard deviations of ≤0.26 on the natural log scale. For binary predictors, we had 80%
power (α = 0.05) to detect an approximately 60% absolute difference in proportions (ie, 5%
vs 65%). Power calculations were performed in PASS v. 1242 and R (ssize.fdr).39
Ethical Considerations
The Intermountain Medical Center institutional review board approved this study. All
patients or their surrogates provided written informed consent. Where possible, patient
reconsent was obtained after initial surrogate consent. A deidentified file of gene count
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(log2-normalized) data and relevant covariates is provided as a Supplementary Material to
this manuscript.

Results

Author Manuscript

As outlined in Figure 1, we screened 631 patients, of whom 105 met eligibility criteria.
Among those 105 patients, we enrolled 40 patients. One withdrew from the study before
any study procedures and requested that data not be collected; 1 withdrew from the study
after baseline data collection, and 4 (11%) died before follow-up. Among 34 follow-upeligible patients, 31 (91%) had the primary outcome measured (N = 30) or imputed from
a regression on 3-month outcomes (N = 1). One patient was excluded from analysis based
on low-quality RNA after extraction. The analytic data sample was thus 30 patients. Table 1
displays the distribution of relevant predictors and hospital outcomes on all patients. Table
S1 in the Supplemental Material displays baseline characteristics among enrolled patients
and the subset within the analytic cohort.
Among the 30 analyzed patients, the mean Hayling test score was 5.8 (standard deviation
1.1); 6 (20%) had impairment of executive function as measured by an abnormal Hayling
result.
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Weighted network analysis identified the network module containing APOE, which was the
largest module and was dominated by low expression transcripts. The gene ontology terms
within relevant WNA modules are displayed in Table S2 of the Supplementary Material.
Distribution of module eigengenes by cognitive impairment is displayed in Table S3 of the
Supplementary Material. The eigengene of the module containing APOE was not associated
with cognitive impairment as measured by an abnormal 6-month Hayling test (P = .6). A
sensitivity analysis using linear regression of the raw 6-month Hayling test, controlling for
age and sex, also did not identify a significant association with the APOE module eigengene
(P = .8). No other network module showed significant association with the Hayling scores
after correction for multiple comparisons. More complete results of WNA, including module
membership for differentially expressed genes (Table S4), are reported in the Supplementary
Material.
In our post hoc exploratory analysis using traditional bioinformatics methods, we identified
228 significant genes between abnormal versus normal including 54 upregulated and 174
downregulated genes. A heatmap comparing gene expression from the top 20 up- and
downregulated genes and a volcano plot are displayed in Figure 2A and B.
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Several transcripts clustered into multiple biological pathways that were suggested to be
differentially activated or suppressed on the basis of Gene Set Enrichment Analysis (Table
S5 in the Supplementary Material).43 Pathways included those related to general cellular
function (eg, ribosome, proteasome, and oxidative phosphorylation) and specific disease
states (eg, Parkinson disease, Alzheimer disease, and Huntington disease). Some of the
potential genes of interest include the immune molecules CCR1 and TREML4 (lower
expression in cognitive impairment) or the lipid-modulating gene ACP6 (higher expression
in cognitive impairment). In the secondary analysis removing low-expression genes, module
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eigengenes were not significantly associated with outcome (Table S6 in the Supplementary
Material) but an association with oxidative stress was observed (Supplemental results and
Tables S7 and S8 in the Supplementary Material).
In the secondary analysis using delirium in the ICU as the clinical end point, only 1
gene was statistically significant (adjusted P value .04): sidekick cell adhesion molecule 1
(SDK1). The SDK1 gene had higher expression (slightly more than double the expression,
1.2 log2-fold increased expression) in patients with delirium during their ICU stay.

Discussion

Author Manuscript

In this prospective pilot study of patients having sepsis with 6-month follow-up for cognitive
function, we did not identify a relationship between APOE gene transcription in peripheral
blood and postseptic cognitive impairment nor did we identify other meaningful signals in
canonical gene pathways on our primary analysis.
Our study has several advantages. We used a well-validated method for identification of
postseptic cognitive impairment and had excellent cohort retention (>85%). We enrolled
patients prospectively, with timely preservation of RNA and unbiased measurement of
the total transcriptome. We used standard techniques for transcriptome analysis. We also
strictly delineated prespecified primary analysis from our subsequent exploratory analysis
and limited our claims about candidate transcripts in the exploratory analysis.

Author Manuscript

This study was performed as a pilot study to determine whether to undertake further
investigations of APOE within the peripheral blood transcriptome. The primary limitation
of our study is its small size and the attendant risk of type II statistical error (failing to
identify a relationship that truly exists). Although the septic transcriptome has been shown
to vary based on age, we did not have a sufficient sample size to robustly control for age in
our analyses.44 Although there was no promising early signal for APOE, the peripheral
transcriptome may provide insights into cognitive function in larger samples, perhaps
following the pathways, including oxidative stress, suggested in exploratory analyses. The
fact that expression was so consistently low across all patients does argue against a relevant
role for APOE expression in peripheral leukocytes. We prefer to publish these data in order
to mitigate the risk of publication bias leading to overemphasis on positive results.45,46

Author Manuscript

The rationale for exploring APOE has been reasonably strong. Apolipoprotein E is a
lipid-trafficking molecule that is closely associated with Alzheimer disease,47 and other
patterns of progressive cognitive decline.48,49 Polymorphisms in APOE, especially the ∈4
variant, have been associated with cognitive impairment after traumatic brain injury,50
(albeit with conflicting information50–53) as well as carbon monoxide poisoning and general
critical illness.54,55 Lipid peroxidation may play a particularly important role in cognitive
impairment after sepsis,56,57 and APOE appears to be related to the burden of lipid
peroxidation in experimental models.56 Early human data suggest that circulating APOE
levels are associated with sepsis per se,58,59 probably reflecting the importance of APOE
to presentation of lipid antigens from invading microorganisms.60 Our results are limited
by our use of RNA transcripts in peripheral blood cells, while APOE expression is likely
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more important in other cell lines, especially neurons. However, neurons are unavailable
for analysis in individuals in whom cognition can be measured. We analyzed the peripheral
transcriptome given the safety and accessibility of those cells and potential relevance in
other disease states;21–26 we cannot comment on the role of APOE expression in postseptic
cognitive impairment in other cell types. We also note as a limitation that we did not
explore genetic polymorphisms within APOE, but rather messenger RNA expression levels
in peripheral leukocytes. It is possible that APOE gene variants are in fact associated with
sepsis-associated cognitive impairment; future work should address that question.

Conclusions

Author Manuscript

In a prospective pilot cohort of patients with sepsis admitted to the ICU, APOE
expression levels were low in peripheral leukocytes and appeared unrelated to executive
cognitive function at 6 months after sepsis hospitalization. Other avenues than peripheral
transcriptomics should likely be undertaken to further interrogate the relationship between
APOE (including its polymorphisms) and sepsis-associated cognitive impairment. Other
lines of inquiry, including oxidation, are suggested.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.

Patient flow diagram depicting the identification of patients for this study.
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Figure 2.

A, Volcano plot of differentially expressed genes. B, Heatmap of gene expression for top 20
up- and downregulated transcripts, by participants.
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